Technical bulletin: Nitrosamines: Questioning the current analytical approach
We look at the challenges posed in regards to nitrosamine testing methodologies and the way in which to move forward to ensure safer drug products.
In recent years, multiple drug products (DPs) have been recalled following the discovery of nitrosamine impurities. Consequently, regulators and the pharmaceutical industry are working hard to identify sources of nitrosamine impurities.
The latest US Food and Drug Administration (FDA) guidance from 2020 lists at least seven potential root causes, while the most recent guidance by the European Medical Agency (EMA) lists eleven. The variety in the possible root causes makes accurate risk assessment a challenging proposition. In this white paper, we look at the challenges posed in regards to testing methodologies and the way in which to move forward to ensure safer DPs.
Related content from this organisation
- Technical bulletin: Nitrosamines: Questioning the current analytical approach
- Quality driven solutions from discovery to commercialisation
- SGS experts help to mitigate the risk of nitrosamine impurities in drug products
- Guide to Outsourcing
- Article: Analytical Quality by Design (AQBD) approach to support analytics optimisation strategy